Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2071 vs Cleviprex in Hypertensive Emergency
NCT05922436Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2023
- Primary completion
- May 2024
01
Overview
Phase 3, randomised, double-blind trial of QLG2071 in hypertensive emergency (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Percentage of patients reaching target SBP range at 30 months. Status: unknown.
02
Drugs
QLG2071
03
Conditions
hypertensive emergency
Beyond the preview
Go deeper on NCT05922436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922436.